Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

  • Herencia-Ropero, Andrea|||0009-0002-9448-1484
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Staniszewska, Anna D.
  • Domènech-Vivó, Joanna|||0000-0002-8049-7488
  • García-Galea, Eduardo|||0000-0003-4699-0786
  • Moles-Fernández, Alejandro|||0000-0003-0252-6084
  • Pedretti, Flaminia
  • Domènech, Heura
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Arenas, Enrique
  • Verdaguer, Helena|||0000-0001-6163-382X
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Talbot, Sara
  • Tobalina, Luis
  • Leo, Elisabetta
  • Lau, Alan|||0000-0003-1055-9812
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Diez, Orland|||0000-0001-7339-0570
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Forment, Josep V.|||0000-0002-7797-2583
  • O'Connor, Mark J.|||0000-0003-1823-625X
  • Albertella, Mark Robert
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Serra, Violeta|||0000-0001-6620-1065
Background: Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is sufficient to cause synthetic lethality in tumors with homologous recombination deficiency (HRD), PARP1 selective inhibitors such as saruparib (AZD5305) are being developed. It is expected that selective PARP1 inhibition leads to a safer profile that facilitates its combination with other DNA damage repair inhibitors. Here, we aimed to characterize the antitumor activity of AZD5305 in patient-derived preclinical models compared to the first-generation PARP1/2 inhibitor olaparib and to identify mechanisms of resistance. Methods: Thirteen previously characterized patient-derived tumor xenograft (PDX) models from breast, ovarian, and pancreatic cancer patients harboring germline pathogenic alterations in BRCA1, BRCA2, or PALB2 were used to evaluate the efficacy of AZD5305 alone or in combination with carboplatin or an ataxia telangiectasia and Rad3 related (ATR) inhibitor (ceralasertib) and compared it to the first-generation PARPi olaparib. We performed DNA and RNA sequencing as well as protein-based assays to identify mechanisms of acquired resistance to either PARPi. Results: AZD5305 showed superior antitumor activity than the first-generation PARPi in terms of preclinical complete response rate (75% vs. 37%). The median preclinical progression-free survival was significantly longer in the AZD5305-treated group compared to the olaparib-treated group (.
Repisalud
Publication Artículo científico (JournalArticle)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocio G
  • Lopez, Virginia
  • Bayón, Gustavo F
  • Diaz de la Guardia, Rafael
  • Sierra, Marta I
  • García-Toraño, Estela
  • Perez, Raúl F
  • García, María G
  • Carella, Antonella
  • Pruneda, Patricia C
  • Prieto, Cristina
  • Dmitrijeva, Marija
  • Santamarina, Pablo
  • Belmonte, Thalia
  • Mangas, Cristina
  • Diaconu, Elena
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón
  • Fernandez-Morera, Juan Luis
  • Bravo, Cristina
  • Bueno, Clara
  • Sanjuan-Pla, Alejandra
  • Rodriguez, Ramon M
  • Suarez-Alvarez, Beatriz
  • López-Larrea, Carlos
  • Bernal, Teresa
  • Colado, Enrique
  • Balbín, Milagros
  • García-Suarez, Olivia
  • Chiara, María Dolores
  • Sáenz-de-Santa-María, Inés
  • Rodríguez, Francisco
  • Pando-Sandoval, Ana
  • Rodrigo, Luis
  • Santos, Laura
  • Salas, Ana
  • Vallejo-Díaz, Jesús
  • C Carrera, Ana
  • Rico, Daniel
  • Hernández-López, Inmaculada
  • Vayá, Amparo
  • Ricart, José M
  • Seto, Edward
  • Sima-Teruel, Núria
  • Vaquero, Alejandro
  • Valledor, Luis
  • Cañal, Maria Jesus
  • Pisano, David
  • Graña Castro, Osvaldo
  • Thomas, Tim
  • Voss, Anne K
  • Menéndez, Pablo
  • Villar-Garea, Ana
  • Deutzmann, Rainer
  • Fernandez, Agustín F
  • Fraga, Mario F
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death.
Repisalud
Publication Artículo científico (JournalArticle)

Deregulation of the imprinted DLK1-DIO3 locus ncRNAs is associated with replicative senescence of human adipose-derived stem cells

  • Garcia-Lopez, Silvia
  • Albo-Castellanos, Carmen
  • Urdinguio, Rocio G
  • Canon, Susana
  • Sanchez-Cabo, Fatima
  • Martínez-Serrano, Alberto
  • Fraga, Mario F
  • Bernad, Antonio
BACKGROUND: Human adult adipose-derived stem cells (hADSCs) have become the most promising cell source for regenerative medicine. However the prolonged ex vivo expansion periods required to obtain the necessary therapeutic dose promotes progressive senescence, with the concomitant reduction of their therapeutic potential. AIM AND SCOPE: A better understanding of the determinants of hADSC senescence is needed to improve biosafety while preserving therapeutic efficiency. Here, we investigated the association between deregulation of the imprinted DLK1-DIO3 region and replicative senescence in hADSC cultures. METHODS: We compared hADSC cultures at short (PS) and prolonged (PL) passages, both in standard and low [O2] (21 and 3%, respectively), in relation to replicative senescence. hADSCs were evaluated for expression alterations in the DLK1-DIO3 region on chromosome 14q32, and particularly in its main miRNA cluster. RESULTS: Comparison of hADSCs cultured at PL or PS surprisingly showed a quite significant fraction (69%) of upregulated miRNAs in PL cultures mapping to the imprinted 14q32 locus, the largest miRNA cluster described in the genome. In agreement, expression of the lncRNA MEG3 (Maternally Expressed 3; Meg3/Gtl2), cultured at 21 and 3% [O2], was also significantly higher in PL than in PS passages. During hADSC replicative senescence the AcK16H4 activating mark was found to be significantly associated with the deregulation of the entire DLK1-DIO3 locus, with a secondary regulatory role for the methylation of DMR regions. CONCLUSION: A direct relationship between DLK1-DIO3 deregulation and replicative senescence of hADSCs is reported, involving upregulation of a very significant fraction of its largest miRNA cluster (14q32.31), paralleled by the progressive overexpression of the lncRNA MEG3, which plays a central role in the regulation of Dlk1/Dio3 activation status in mice.
Repisalud
Publication Artículo científico (JournalArticle)

Age-associated hydroxymethylation in human bone-marrow mesenchymal stem cells

  • Toraño, Estela G
  • Bayón, Gustavo F
  • del Real, Álvaro
  • Sierra, Marta I
  • García, María G
  • Carella, Antonella
  • Belmonte, Thalia
  • Urdinguio, Rocio G
  • Cubillo, Isabel
  • Garcia-Castro, Javier
  • Delgado-Calle, Jesús
  • Pérez-Campo, Flor M
  • Riancho, José A
  • Fraga, Mario F
  • Fernandez, Agustín F
BACKGROUND: Age-associated changes in genomic DNA methylation have been primarily attributed to 5-methylcytosine (5mC). However, the recent discovery of 5-hydroxymethylcytosine (5hmC) suggests that this epigenetic mark might also play a role in the process. METHODS: Here, we analyzed the genome-wide profile of 5hmc in mesenchymal stem cells (MSCs) obtained from bone-marrow donors, aged 2-89 years. RESULTS: We identified 10,685 frequently hydroxymethylated CpG sites in MSCs that were, as in other cell types, significantly associated with low density CpG regions, introns, the histone posttranslational modification H3k4me1 and enhancers. Study of the age-associated changes to 5hmC identified 785 hyper- and 846 hypo-hydroxymethylated CpG sites in the MSCs obtained from older individuals. CONCLUSIONS: DNA hyper-hydroxymethylation in the advanced-age group was associated with loss of 5mC, which suggests that, at specific CpG sites, this epigenetic modification might play a role in DNA methylation changes during lifetime. Since bone-marrow MSCs have many clinical applications, and the fact that the epigenomic alterations in this cell type associated with aging identified in this study could have associated functional effects, the age of donors should be taken into account in clinical settings.
RUA. Repositorio Institucional de la Universidad de Alicante
Publication Otros (Other)

Descolonización de la música en TikTok: “¡Hagamos un dúo!”, Decolonising the music on TikTok: “Let’s duet!”

  • Vizcaíno-Verdú, Arantxa
En la actualidad, redes sociales como TikTok están transformando el modo en que se expanden las narrativas musicales por el mundo. En esta aplicación de micro-vídeos eminentemente musicales, se comparten diariamente diversidad de contenidos creativos que no se alejan de los contextos socioculturales de sus usuarios. En este sentido, la plataforma facilita la creación de contenido “migrante” no occidental, integrando valores que reflejan el crecimiento cultural, social, rural y oriental. Con base en 510 dúos musicales generados por los usuarios de TikTok, este estudio explora cómo la plataforma potencia la descolonización de la industria musical, gobernada hasta entonces por estudios de grabación occidentales. Se desarrolla un análisis semiótico para explorar el contenido generado por el usuario en torno al reto #SingWithMe. Los resultados apuntan hacia un proceso de redescubrimiento y recuperación, sueño, compromiso y acción para la emancipación industrial. Se concluye que el dúo de TikTok es una herramienta clave que despierta una suerte de descentralización popular inconsciente dirigida por los usuarios.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

  • Òdena, Andreu
  • Casals, Eloi
  • Molina, Cristina
  • Coşkun, Meriç
  • Guzman Torres, Marta
  • Brasó Maristany, Fara
  • García-Galea, Eduardo
  • Herencia Ropero, Andrea
  • Domènech Garcia, Heura
  • Rodríguez, Olga
  • Grueso, Judit
  • Dienstmann, Rodrigo
  • Oliveira, Mafalda
  • Monserrat, Laia
  • Serra, Violeta
Patritumab deruxtecan; Xenografts; Breast cancer, Patritumab deruxtecan; Xenoinjertos; Cáncer de mama, Patritumab deruxtecan; Xenoempelt; Càncer de mama, Novel antibody-drug conjugates (ADCs) have shown potent antitumor activity across multiple cancer types. However, the key determinants of therapeutic response remain under investigation. In this study, we aimed to identify potential determinants of long-term response to patritumab deruxtecan (HER3-DXd; MK-1022), a HER3-directed ADC linked to a potent topoisomerase I inhibitor (TOP1i) payload, using a cohort of thirty-one breast cancer (BC) patient-derived xenograft (PDX) models. Fourteen out of 31 (45%) PDXs exhibited a profound and sustained response to HER3-DXd. Basal-like PAM50 intrinsic subtype, limited prior exposure to chemotherapy and intrinsic sensitivity to the TOP1i irinotecan were associated with long-term response. Additionally, HER3-DXd showed sustained activity in BRCA1/BRCA2-mutated PARPi-resistant PDX models. Long-term responders exhibited persistent DNA damage and lacked early transcriptional activation of the G2/M cell cycle checkpoint that allow for DNA repair and RNA-DNA hybrid (R-loop) resolution, in parallel resulting in immune pathways transcriptional activation. Notably, characteristics linked to long-term response were primarily associated with the TOP1i payload activity., VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA program from the Generalitat de Catalunya for their support on this research. This study was supported by the Asociación Española Cáncer de Mama Metastásico (AECMM) (III Metapremio M. Chiara Giorgetti 2021) and by the Catalan Agency AGAUR-FEDER (2021 SGR 01510 to V. Serra). V. Serra received funds from the Instituto de Salud Carlos III (ISCIII), and co-funded by the European Union (PI20/00892 and CPII19/00033). The FERO Foundation and GHD also provided support to V. Serra. A. Òdena and L. Monserrat received fellowships from the Agency for Management of University and Research Grants (2022 FI_B 00664 and AGAUR 2019 FI_B 01199, respectively). F. Brasó-Maristany received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). A. Herencia-Ropero received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). F. Pedretti received a fellowship from La Caixa Foundation (ID 100010434) (LCF/BQ/DI19/11730051). H. Domènech received a Severo Ochoa fellowship from the Spanish Ministry of Science and Innovation (PRE2021-099087). A. Esteve-Codina. reports that Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. S. Chandarlapaty is supported by MSK Cancer Center Support Grant P30 CA008748 and the BCRF. A. Prat received funding from the Breast Cancer Research Foundation (BCRF-22-198, BCRF-23-198, BCRF-24-198), Beca Marta Santamaría, Fundación CRIS contra el Cancer (PR_EX_2021-14), Agència de Gestó d’Ajuts Universitaris I de Recerca (2021 SGR 01156), Fundación Fero (ONCOXXI21), Asociación Cáncer de Mama Metastásico (IV Premios M. Chiara Giorgetti), PI22/01017: funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and RESCUER: funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. We would like to acknowledge Daiichi Sankyo and Merck Inc. for providing the HER3-DXd and the IgG-DXd and Astrazeneca Inc. for supplying the olaparib used in the study. Finally, we would like to acknowledge the patients who donate samples for the generation of the PDX models used in this study.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

  • Rodriguez, María Jimena
  • Perrone, María Cecilia
  • Riggio, Marina
  • Palafox Sánchez, Marta
  • Salinas, Valeria
  • Elia, Andres
  • Serra Elizalde, Violeta
Cancer; Cell biology, Càncer; Biologia cel·lular, Cáncer; Biología celular, Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel therapeutic strategies to delay disease progression and improve patient survival. Here, we assessed the mechanisms of acquired resistance using T47D and MCF-7 tamoxifen- and palbociclib-resistant cell-line variants in culture and as xenografts, and patient-derived cells (PDCs) obtained from sensitive or resistant patient-derived xenografts (PDXs). In these models, we analyzed the effect of specific kinase inhibitors on survival, signaling and cellular aggressiveness. Our results revealed that mTOR inhibition is more effective than PI3K inhibition in overcoming resistance, irrespective of PIK3CA mutation status, by decreasing cell proliferation and tumor growth, as well as reducing cell migration and stemness. Moreover, a combination of mTOR and CDK4/6 inhibitors may prevent pathway reactivation downstream of PI3K, interfering with the survival of resistant cells and consequent tumor escape. In conclusion, we highlight the benefits of incorporating mTOR inhibitors into the current therapy in ER + breast cancer. This alternative therapeutic strategy not only enhances the antitumor response but may also delay the emergence of resistance and tumor recurrence., This work was supported by CONICET, ANPCYT (Grants PICT2509 & PICT0345), Instituto Nacional del Cáncer (Grants 2016 & 2018), Fundación Williams, Fundación Bunge & Born (Oster Grant) (Argentina); Instituto de Salud Carlos III (Grants PI20/00892 & CPII19/0033), Ministerio de Economía y Competitividad (FJCI-2015-25412) (Spain).
Docta Complutense
Publication Artículo científico (JournalArticle)

Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma

  • López, Virginia
  • Tejedor, Juan Ramón
  • Carella, Antonella
  • García, María G.
  • Santamarina-Ojeda, Pablo
  • Pérez, Raúl F.
  • Mangas, Cristina
  • Urdinguio, Rocío G.
  • Aranburu, Aitziber
  • de la Nava, Daniel
  • Corte-Torres, María D.
  • Astudillo, Aurora
  • Mollejo, Manuela
  • Meléndez, Bárbara
  • Fernández, Agustín F.
  • Fraga, Mario F.
Glioblastoma multiforme (GBM) is the most common and aggressive type of brain tumor in adulthood. Epigenetic mechanisms are known to play a key role in GBM although the involvement of histone methyltransferase KMT5B and its mark H4K20me2 has remained largely unexplored. The present study shows that DNA hypermethylation and loss of DNA hydroxymethylation is associated with KMT5B downregulation and genome-wide reduction of H4K20me2 levels in a set of human GBM samples and cell lines as compared with non-tumoral specimens. Ectopic overexpression of KMT5B induced tumor suppressor-like features in vitro and in a mouse tumor xenograft model, as well as changes in the expression of several glioblastoma-related genes. H4K20me2 enrichment was found immediately upstream of the promoter regions of a subset of deregulated genes, thus suggesting a possible role for KMT5B in GBM through the epigenetic modulation of key target cancer genes.
Docta Complutense
Publication Artículo científico (JournalArticle)

Epigenetic dysregulation of TET2 in human glioblastoma

  • García, María G.
  • Carella, Antonella
  • Urdinguio, Rocío G.
  • Bayón, Gustavo F.
  • Lopez, Virginia
  • Tejedor, Juan Ramón
  • Sierra, Marta I.
  • García-Toraño, Eestela
  • Santamarina, Pablo
  • Pérez, Raúl. F.
  • Mangas, Cristina
  • Astudillo, Aurora
  • Corte-Torres, M. Daniela
  • Sáenz-de-Santa-María, Inés
  • Chiara, María-Dolores
  • Fernández, Agustín F.
  • Fraga, Mario F.
Ten-eleven translocation (TET) enzymes are frequently deregulated in cancer, but the underlying molecular mechanisms are still poorly understood. Here we report that TET2 shows frequent epigenetic alterations in human glioblastoma including DNA hypermethylation and hypo-hydroxymethylation, as well as loss of histone acetylation. Ectopic overexpression of TET2 regulated neural differentiation in glioblastoma cell lines and impaired tumor growth. Our results suggest that epigenetic dysregulation of TET2 plays a role in human glioblastoma.
Docta Complutense
Publication Artículo científico (JournalArticle)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocío G.
  • Lopez, Virginia
  • Bayón, Gustavo F.
  • Diaz de la Guardia, Rafael
  • Sierra, Marta I.
  • García Toraño, Estela
  • Perez, Raúl F
  • García, María G.
  • Carella, Antonella
  • Pruneda, Patricia C.
  • Prieto, Cristina
  • Dmitrijeva, Marija
  • Santamarina, Pablo
  • Belmonte, Thalía
  • Mangas, Cristina
  • Diaconu, Elena
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón
  • Fernandez Morera, Juan Luis
  • Bravo, Cristina
  • Bueno, Clara
  • Sanjuan Pla, Alejandra
  • Rodriguez, Ramón M.
  • Suarez Alvarez, Beatriz
  • López Larrea, Carlos
  • Bernal, Teresa
  • Colado, Enrique
  • Balbín, Milagros
  • García Suarez, Olivia
  • Chiara, Maria Dolores
  • Sáenz de Santa María, Inés
  • Rodríguez, Francisco
  • Pando Sandoval, Ana
  • Rodrigo, Luis
  • Santos, Laura
  • Salas, Ana
  • Vallejo Díaz, Jesús
  • Carrera, Ana C.
  • Rico, Daniel
  • Hernández López, Inmaculada
  • Vayá, Amparo
  • Ricart, José M.
  • Seto, Edward
  • Sima Teruel, Núria
  • Vaquero, Alejandro
  • Valledor, Luis
  • Cañal, Maria Jesus
  • Pisano, David
  • Graña Castro, Osvaldo
  • Thomas, Tim
  • Voss, Anne K.
  • Menéndez, Pablo
  • Villar Garea, Ana
  • Deutzmann, Rainer
  • Fernandez, Agustín F.
  • Fraga, Mario F.
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

  • Urdinguio, Rocío G.|||0000-0003-2736-5758
  • López, Virginia|||0000-0002-0065-7999
  • Fernández Bayón, Gustavo|||0000-0002-0763-0473
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Sierra, Marta I.
  • García-Toraño, Estela
  • Pérez, Raúl F.|||0000-0003-4336-9898
  • García, María G.
  • Carella, Antonella
  • Pruneda, Patricia C.
  • Prieto, Cristina|||0000-0002-0812-8100
  • Dmitrijeva, Marija
  • Santamarina-Ojeda, Pablo|||0000-0002-7439-8467
  • Belmonte, Thalia|||0000-0003-1241-6073
  • Mangas, Cristina
  • Diaconu, Elena|||0000-0002-2115-4311
  • Ferrero, Cecilia
  • Tejedor, Juan Ramón|||0000-0002-4061-9698
  • Fernandez-Morera, Juan Luis|||0000-0003-1244-068X
  • Bravo, Cristina
  • Bueno, Clara|||0000-0003-1442-6216
  • Sanjuan-Pla, Alejandra
  • Rodríguez López, Ramón María|||0000-0002-6770-5123
  • Suárez-Álvarez, Beatriz|||0000-0002-3431-4206
  • López-Larrea, Carlos
  • Bernal, Teresa|||0000-0002-2338-513X
  • Colado, Enrique|||0000-0001-8675-8207
  • Balbín, Milagros|||0000-0001-5325-0407
  • García-Suarez, Olivia
  • Chiara, María Dolores|||0000-0002-1112-1583
  • Sáenz De Santa María, Inés|||0000-0002-1868-3001
  • Rodríguez, Francisco|||0000-0001-7909-932X
  • Pando-Sandoval, Ana|||0000-0002-7923-9107
  • Rodrigo-Sáez, Luis|||0000-0003-1717-9345
  • Santos, Laura|||0000-0002-6194-0683
  • Salas, Ana
  • Vallejo-Díaz, Jesús
  • Carrera, Ana C.
  • Rico, Daniel|||0000-0002-6561-2310
  • Hernández-López, Inmaculada
  • Vayá, Amparo
  • Ricart, José María
  • Seto, Edward
  • Sima, Núria|||0000-0003-4097-1402
  • Vaquero, Alejandro|||0000-0002-8735-4156
  • Valledor, Luís|||0000-0002-0636-365X
  • Cañal Villanueva, María Jesús Fátima|||0000-0002-1639-9672
  • Pisano, David|||0000-0002-4895-4124
  • Graña-Castro, Osvaldo
  • Thomas, Tim|||0000-0002-7623-8344
  • Voss, Anne Kathrin|||0000-0002-3853-9381
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Villar-Garea, Ana|||0000-0001-8960-1635
  • Deutzmann, Rainer
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fraga, Mario|||0000-0001-8450-2603
Histone H4 acetylation at Lysine 16 (H4K16ac) is a key epigenetic mark involved in gene regulation, DNA repair and chromatin remodeling, and though it is known to be essential for embryonic development, its role during adult life is still poorly understood. Here we show that this lysine is massively hyperacetylated in peripheral neutrophils. Genome-wide mapping of H4K16ac in terminally differentiated blood cells, along with functional experiments, supported a role for this histone post-translational modification in the regulation of cell differentiation and apoptosis in the hematopoietic system. Furthermore, in neutrophils, H4K16ac was enriched at specific DNA repeats. These DNA regions presented an accessible chromatin conformation and were associated with the cleavage sites that generate the 50 kb DNA fragments during the first stages of programmed cell death. Our results thus suggest that H4K16ac plays a dual role in myeloid cells as it not only regulates differentiation and apoptosis, but it also exhibits a non-canonical structural role in poising chromatin for cleavage at an early stage of neutrophil cell death.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Conservation of Aging and Cancer Epigenetic Signatures across Human and Mouse

  • Pérez, Raúl F.|||0000-0003-4336-9898
  • Tejedor, Juan Ramón|||0000-0002-4061-9698
  • Santamarina-Ojeda, Pablo|||0000-0002-7439-8467
  • Martínez, Virginia López
  • Urdinguio, Rocío G.|||0000-0003-2736-5758
  • Villamañán, Lucía
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Sarró, N. mí Vidal
  • Barradas, Marta
  • Fernandez-Marcos, Pablo Jose
  • Serrano, Manuel|||0000-0001-7177-9312
  • Fernández, Agustín F|||0000-0002-3792-4085
  • Fraga, Mario|||0000-0001-8450-2603
Aging and cancer are two interrelated processes, with aging being a major risk factor for the development of cancer. Parallel epigenetic alterations have been described for both, although differences, especially within the DNA hypomethylation scenario, have also been recently reported. Although many of these observations arise from the use of mouse models, there is a lack of systematic comparisons of human and mouse epigenetic patterns in the context of disease. However, such comparisons are significant as they allow to establish the extent to which some of the observed similarities or differences arise from pre-existing species-specific epigenetic traits. Here, we have used reduced representation bisulfite sequencing to profile the brain methylomes of young and old, tumoral and nontumoral brain samples from human and mouse. We first characterized the baseline epigenomic patterns of the species and subsequently focused on the DNA methylation alterations associated with cancer and aging. Next, we described the functional genomic and epigenomic context associated with the alterations, and finally, we integrated our data to study interspecies DNA methylation levels at orthologous CpG sites. Globally, we found considerable differences between the characteristics of DNA methylation alterations in cancer and aging in both species. Moreover, we describe robust evidence for the conservation of the specific cancer and aging epigenomic signatures in human and mouse. Our observations point toward the preservation of the functional consequences of these alterations at multiple levels of genomic regulation. Finally, our analyses reveal a role for the genomic context in explaining disease- and species-specific epigenetic traits.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Response Variability to Drug Testing in Two Models of Chemically Induced Colitis

  • Suau, Roger|||0000-0003-3754-4768
  • Garcia, Anna
  • Bernal, Carla
  • Llaves, Mariona
  • Schiering, Katharina
  • Jou-Ollé, Eva
  • Pertegaz, Alex
  • Garcia-Jaraquemada, Arce|||0000-0001-6603-2003
  • Bartolí, Ramon
  • Lorén, Violeta
  • Vergara, Patri|||0000-0002-9220-6406
  • Mañosa i Ciria, Míriam|||0000-0002-9051-2581
  • Domènech, Eugeni|||0000-0002-2315-7196
  • Manyé, Josep|||0000-0002-3121-8016
The lack of knowledge regarding the pathogenesis of IBD is a challenge for the development of more effective and safer therapies. Although in vivo preclinical approaches are critical for drug testing, none of the existing models accurately reproduce human IBD. Factors that influence the intra-individual response to drugs have barely been described. With this in mind, our aim was to compare the anti-inflammatory efficacy of a new molecule (MTADV) to that of corticosteroids in TNBS and DSS-induced colitis mice of both sexes in order to clarify further the response mechanism involved and the variability between sexes. The drugs were administered preventively and therapeutically, and real-time bioluminescence was performed for the in vivo time-course colitis monitoring. Morphometric data were also collected, and colonic cytokines and acute plasma phase proteins were analyzed by qRT-PCR and ELISA, respectively-bioluminescence images correlated with inflammatory markers. In the TNBS model, dexamethasone worked better in females, while MTADV improved inflammation in males. In DSS-colitis, both therapies worked similarly. Based on the molecular profiles, interaction networks were constructed to pinpoint the drivers of therapeutic response that were highly dependent on the sex. In conclusion, our results suggest the importance of considering sex in IBD preclinical drug screening.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer

  • Palafox, Marta|||0000-0002-1762-3250
  • Monserrat, Laia|||0000-0002-8802-3033
  • Bellet Ezquerra, Meritxell|||0000-0001-8859-8307
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Oliveira, Mafalda|||0000-0001-9152-8799
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Ibrahimi, Nusaibah|||0000-0003-4537-0323
  • Kannan, Srinivasaraghavan|||0000-0002-9539-5249
  • Mina, Leonardo
  • Herrera-Abreu, Maria Teresa
  • Òdena, Andreu|||0000-0003-1529-880X
  • Sánchez Guixé, Mònica|||0000-0002-9430-4413
  • Capelán, Marta
  • Azaro, Analía
  • Bruna, Alejandra|||0000-0003-1214-9665
  • Rodríguez, Olga|||0000-0002-0123-9975
  • Guzmán, Marta|||0000-0002-0924-9887
  • Grueso, Judit|||0000-0003-1093-7940
  • Viaplana, Cristina|||0000-0001-8904-4330
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Su, Faye
  • Lin, Kui
  • Clarke, Robert B.|||0000-0001-5407-3123
  • Caldas, Carlos|||0000-0003-3547-1489
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Michiels, Stefan|||0000-0002-6963-2968
  • García-Sanz, Alicia
  • Turner, Nicholas C.|||0000-0001-8937-0873
  • Prat, Aleix|||0000-0003-2377-540X
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Verma, Chandra S.
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Scaltriti, Maurizio|||0000-0002-5522-1447
  • Arnedos, Monica
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Serra, Violeta|||0000-0001-6620-1065
CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts (n = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors (n = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies. CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models

  • Rodriguez, María Jimena
  • Perrone, María Cecilia
  • Riggio, Marina
  • Palafox Sánchez, Marta
  • Salinas, Valeria
  • Elia, Andres
  • Serra Elizalde, Violeta
Cancer; Cell biology, Càncer; Biologia cel·lular, Cáncer; Biología celular, Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel therapeutic strategies to delay disease progression and improve patient survival. Here, we assessed the mechanisms of acquired resistance using T47D and MCF-7 tamoxifen- and palbociclib-resistant cell-line variants in culture and as xenografts, and patient-derived cells (PDCs) obtained from sensitive or resistant patient-derived xenografts (PDXs). In these models, we analyzed the effect of specific kinase inhibitors on survival, signaling and cellular aggressiveness. Our results revealed that mTOR inhibition is more effective than PI3K inhibition in overcoming resistance, irrespective of PIK3CA mutation status, by decreasing cell proliferation and tumor growth, as well as reducing cell migration and stemness. Moreover, a combination of mTOR and CDK4/6 inhibitors may prevent pathway reactivation downstream of PI3K, interfering with the survival of resistant cells and consequent tumor escape. In conclusion, we highlight the benefits of incorporating mTOR inhibitors into the current therapy in ER + breast cancer. This alternative therapeutic strategy not only enhances the antitumor response but may also delay the emergence of resistance and tumor recurrence., This work was supported by CONICET, ANPCYT (Grants PICT2509 & PICT0345), Instituto Nacional del Cáncer (Grants 2016 & 2018), Fundación Williams, Fundación Bunge & Born (Oster Grant) (Argentina); Instituto de Salud Carlos III (Grants PI20/00892 & CPII19/0033), Ministerio de Economía y Competitividad (FJCI-2015-25412) (Spain).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts

  • Òdena, Andreu
  • Casals, Eloi
  • Molina, Cristina
  • Coşkun, Meriç
  • Guzman Torres, Marta
  • Brasó Maristany, Fara
  • García-Galea, Eduardo
  • Herencia Ropero, Andrea
  • Domènech Garcia, Heura
  • Rodríguez, Olga
  • Grueso, Judit
  • Dienstmann, Rodrigo
  • Oliveira, Mafalda
  • Monserrat, Laia
  • Serra, Violeta
Patritumab deruxtecan; Xenografts; Breast cancer, Patritumab deruxtecan; Xenoinjertos; Cáncer de mama, Patritumab deruxtecan; Xenoempelt; Càncer de mama, Novel antibody-drug conjugates (ADCs) have shown potent antitumor activity across multiple cancer types. However, the key determinants of therapeutic response remain under investigation. In this study, we aimed to identify potential determinants of long-term response to patritumab deruxtecan (HER3-DXd; MK-1022), a HER3-directed ADC linked to a potent topoisomerase I inhibitor (TOP1i) payload, using a cohort of thirty-one breast cancer (BC) patient-derived xenograft (PDX) models. Fourteen out of 31 (45%) PDXs exhibited a profound and sustained response to HER3-DXd. Basal-like PAM50 intrinsic subtype, limited prior exposure to chemotherapy and intrinsic sensitivity to the TOP1i irinotecan were associated with long-term response. Additionally, HER3-DXd showed sustained activity in BRCA1/BRCA2-mutated PARPi-resistant PDX models. Long-term responders exhibited persistent DNA damage and lacked early transcriptional activation of the G2/M cell cycle checkpoint that allow for DNA repair and RNA-DNA hybrid (R-loop) resolution, in parallel resulting in immune pathways transcriptional activation. Notably, characteristics linked to long-term response were primarily associated with the TOP1i payload activity., VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA program from the Generalitat de Catalunya for their support on this research. This study was supported by the Asociación Española Cáncer de Mama Metastásico (AECMM) (III Metapremio M. Chiara Giorgetti 2021) and by the Catalan Agency AGAUR-FEDER (2021 SGR 01510 to V. Serra). V. Serra received funds from the Instituto de Salud Carlos III (ISCIII), and co-funded by the European Union (PI20/00892 and CPII19/00033). The FERO Foundation and GHD also provided support to V. Serra. A. Òdena and L. Monserrat received fellowships from the Agency for Management of University and Research Grants (2022 FI_B 00664 and AGAUR 2019 FI_B 01199, respectively). F. Brasó-Maristany received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). A. Herencia-Ropero received funding from Generalitat de Catalunya (PERIS SLT017/20/000081). F. Pedretti received a fellowship from La Caixa Foundation (ID 100010434) (LCF/BQ/DI19/11730051). H. Domènech received a Severo Ochoa fellowship from the Spanish Ministry of Science and Innovation (PRE2021-099087). A. Esteve-Codina. reports that Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. S. Chandarlapaty is supported by MSK Cancer Center Support Grant P30 CA008748 and the BCRF. A. Prat received funding from the Breast Cancer Research Foundation (BCRF-22-198, BCRF-23-198, BCRF-24-198), Beca Marta Santamaría, Fundación CRIS contra el Cancer (PR_EX_2021-14), Agència de Gestó d’Ajuts Universitaris I de Recerca (2021 SGR 01156), Fundación Fero (ONCOXXI21), Asociación Cáncer de Mama Metastásico (IV Premios M. Chiara Giorgetti), PI22/01017: funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and RESCUER: funded by European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. We would like to acknowledge Daiichi Sankyo and Merck Inc. for providing the HER3-DXd and the IgG-DXd and Astrazeneca Inc. for supplying the olaparib used in the study. Finally, we would like to acknowledge the patients who donate samples for the generation of the PDX models used in this study.